Nutex Health FY2025 revenue up 82% to $875M, diluted EPS $10.48; announces $25M buyback

Nutex Health Inc.

FY2025 total revenue $875.3M, up 82.4% YoY; net income $70.8M vs $52.1M; diluted EPS $10.48 vs $9.69.
Q4 revenue $151.7M (-41.1% YoY) due to $55M arbitration true-up and $69M arbitration revenue recorded in Q4 2024.
Q4 net income $11.8M vs $61.6M; EBITDA $25.7M vs $78.9M; Adjusted EBITDA $16.6M vs $86.7M.
Board authorized $25M stock repurchase program over 6 months to offset dilution from earn-out shares for hospitals.
Remediated all previously disclosed material weaknesses in internal controls over financial reporting in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.